Most research institutions in India grew up one at a time. Each was founded for its own purpose, in its own city, with its own governing body, accounts office and recruitment rules. That freedom produced good science, but it also produced silos: two institutes a few kilometres apart might buy the same expensive machine, or never discover that they were chasing the same problem. The Biotechnology Research and Innovation Council (BRIC) was created to change that for biotechnology, and its Fourth Annual General Meeting on 21 November 2026 is a chance to check how the experiment is going.
The meeting was held at Kartavya Bhawan, New Delhi, under the chairmanship of Dr Jitendra Singh, Minister of State (Independent Charge) for Science and Technology and Earth Sciences, who is also President of the BRIC Society. Dr Rajesh S. Gokhale, Secretary of the Department of Biotechnology (DBT) and Director General of BRIC, presented the Council's achievements, and Society members, some of them joining virtually, added their suggestions. The Minister repeated two national goals: a US$ 300 billion Indian bioeconomy by 2030 and US$ 1 trillion by 2047.
This article explains what BRIC is, how it works, what the Fourth AGM decided, and the science and policy behind the headline numbers.
The meeting at a glance
| Item | Detail |
|---|---|
| Event | Fourth Annual General Meeting of the BRIC Society |
| Date and place | 21 November 2026, Kartavya Bhawan, New Delhi |
| Chair | Dr Jitendra Singh, President, BRIC Society |
| Presentation | Dr Rajesh S. Gokhale, Secretary, DBT, and Director General, BRIC |
| Launched | BRIC Handbook of Memorandum of Association (MoA), Rules, Regulations and Bye-laws |
| Proposal noted | Dissolution of the existing societies of the constituent autonomous institutions and their merger with BRIC |
| Targets restated | US$ 300 billion bioeconomy by 2030; US$ 1 trillion by 2047 |
What BRIC is, and how it was built
BRIC is an autonomous body under the Department of Biotechnology, which sits in the Ministry of Science and Technology. PIB records that, with Cabinet approval, DBT created BRIC by subsuming 14 of its autonomous institutions on 10 November 2023. DBT itself was established in 1986, and it marked its 40th Foundation Day on 24 February 2026.
The institutions folded into BRIC are premier names in Indian life sciences. PIB releases mention several, such as the National Institute of Immunology (NII) in Delhi, the Regional Centre for Biotechnology (RCB), the Translational Health Science and Technology Institute (THSTI) and the National Agri-Food Biomanufacturing Institute (NABI) at Mohali. NABI was inaugurated in October 2024 and is described by PIB as India's first biomanufacturing institute.
The key design choice is that the institutes kept their individual strengths while joining a shared framework. The Minister described it at the Fourth AGM as a model in which institutions "work collectively, share capabilities and pursue multidisciplinary research while retaining their individual strengths". He also said BRIC was among the first initiatives of its kind in the Government of India and has since inspired similar approaches in other organisations. That claim is the Minister's own, and PIB reports it as his statement.
The machinery of governance
A Council made of fourteen institutes needs a head office. PIB's releases show the building blocks being put in place over three years:
- A Society, chaired by the Minister, which holds the Annual General Meeting and approves the audited accounts. The second AGM (12 December 2024) approved the accounts for 2023-24 and launched the first Annual Report.
- A Governing Body and Finance Committee, and a centralised accounting system, reported at the second AGM.
- A Secretariat, whose new office complex was inaugurated on 29 December 2025 in New Delhi. PIB calls it a "lean coordinating mechanism" that helps the institutes work together while preserving their autonomy.
- A rulebook. The Fourth AGM launched the BRIC Handbook, which gathers the Memorandum of Association, rules, regulations and bye-laws in one reference.
The Fourth AGM also discussed the last piece of the merger: the dissolution of the separate societies that each institute had, and their merger into the BRIC Society. The release calls it a "proposal" and does not say it was approved, so students should not write it as a settled decision.
What the Fourth AGM reviewed
Research standing. The Minister welcomed BRIC's ranking as first among government institutions in health sciences and second in biological sciences in India for the second consecutive year, as per the Nature Index India. The Nature Index, published by Springer Nature, counts the research articles an institution publishes in a selected set of high-quality science journals. It is a measure of research output, not of commercial or social impact. The Minister himself made that point, saying that scientific achievements must not remain confined to publications and patents but must become technologies, products and solutions.
From laboratory to market. Much of the meeting was about translation. Dr Jitendra Singh asked for stronger engagement between scientists, entrepreneurs, investors and industry from the early stages of a technology's development, because translation "requires capital, mentorship, industry partnerships and a better understanding of market and regulatory pathways". He welcomed the Entrepreneur-in-Residence (EIR) programme, which BRIC and the Biotechnology Industry Research Assistance Council (BIRAC) launched jointly on 10 November 2025, and collaborations on biomanufacturing and technology scale-up.
Talent. The Minister noted that the D.E.S.I.G.N. for BioE3 Challenge had drawn more than 6,000 proposals from school students and citizens across both categories. In November 2025 the same challenge had received about 510 applications, so participation has grown many times over. Society members suggested using Vaibhav Connect, a platform linking the Indian scientific diaspora with research opportunities, to bring scientists working abroad back to Indian institutions, and urged work at the meeting point of artificial intelligence and biology.
People and posts. The Minister welcomed efforts to strengthen research capacity through recruitment against revived scientific positions, along with the operationalisation of the Secretariat.
The bioeconomy numbers
The goals quoted at the AGM rest on a steep growth curve. PIB releases from March 2026 record that India's bioeconomy grew from about US$ 10 billion in 2014 to over US$ 195 billion in 2025. The India Bioeconomy Report 2026, released on 19 March 2026, puts the 2025 figure at US$ 195.3 billion, about 4.8% of GDP, growing at nearly 18% a year. At the Fourth AGM the Minister said the number of biotechnology startups now exceeds 11,000. In February 2026 he had put the figure for 2014 at fewer than 100.
| Year | Bioeconomy size | Source |
|---|---|---|
| 2014 | about US$ 10 billion | PIB, 24 February and 19 March 2026 |
| 2024 | US$ 165.7 billion | PIB, 24 February 2026 |
| 2025 | US$ 195.3 billion (4.8% of GDP) | PIB, India Bioeconomy Report 2026 |
| 2030 | US$ 300 billion (target) | PIB, 21 November 2026 |
| 2047 | US$ 1 trillion (target) | PIB, 21 November 2026 |
What the bioeconomy means. It is the part of the economy that makes things from living systems: medicines and vaccines, enzymes, bio-based plastics and chemicals, improved crops, and fuels made from plant matter. Because it includes industrial products and not only laboratories, it is larger than the "biotech sector" of drug companies alone.
The policy behind it: BioE3
The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy on 24 August 2024. It aims at "high performance biomanufacturing", meaning the ability to produce goods from medicines to materials using advanced biotechnology. PIB lists its thematic sectors:
- high-value bio-based chemicals, biopolymers and enzymes;
- smart proteins and functional foods;
- precision biotherapeutics;
- climate-resilient agriculture;
- carbon capture and its utilisation;
- marine and space research.
The policy promises biomanufacturing hubs, Bio-AI hubs and biofoundries, and links to goals such as net-zero emissions and a circular bioeconomy. Our earlier piece on India's bioeconomy and the BioE3 Policy covers its design in more detail.
A biofoundry is a laboratory facility where biological designs, such as an engineered microbe that makes a useful chemical, can be built and tested quickly, often with automation. PIB reported in February 2026 a National Biofoundry Network of six biofoundries and 21 bio-enabler facilities, and a network of 95 bio-incubators across 21 States and Union Territories supporting more than 1,800 incubatees. At the BRIC level, four biofoundries were reported in November 2025.
The family of institutions
Three bodies are easy to confuse, and they are a classic examination trap.
| Body | What it is | What it does |
|---|---|---|
| DBT | A department of the Ministry of Science and Technology, set up in 1986 | Makes policy, funds research, runs programmes |
| BRIC | Autonomous council under DBT, formed 2023 by merging 14 institutes | Does research through its institutes under shared governance |
| BIRAC | A not-for-profit Section 8 public sector enterprise under DBT; held its 14th Foundation Day in March 2026 | Funds and mentors startups and industry, builds incubators |
In short, DBT sets direction, BRIC does the research and BIRAC carries ideas to the market. The EIR programme is a joint BRIC–BIRAC effort and shows how the two meet.
The science that sits behind the headlines
Three research examples cited by PIB in recent years show what the institutions deliver.
Gene therapy for haemophilia. In December 2024 the Minister announced a successful gene therapy trial for haemophilia, conducted with DBT support at the Christian Medical College, Vellore and reported in the New England Journal of Medicine. Haemophilia is an inherited disorder in which blood does not clot properly because a clotting factor is missing or faulty. Gene therapy tries to supply a working copy of the gene, so that the body makes the factor itself. Basic inheritance is covered in our notes on Mendelian genetics and inheritance.
Vaccines. In November 2025 the Minister listed vaccine work from COVID-19 to HPV, malaria and dengue as a source of India's global reputation. India's single-dose HPV programme against cervical cancer is the subject of our article on 80 lakh HPV doses, and the principles behind vaccines are in our notes on immunity and vaccination.
Climate-resilient agriculture, materials and diagnostics. At the Fourth AGM the Minister referred to research from BRIC institutes in novel therapeutics, diagnostics, disease detection, climate-resilient agriculture and sustainable biomaterials. PIB gives no individual project details, so treat these as areas of work rather than named achievements.
What to watch next
Three questions will show whether the model works. First, whether the merger of societies is completed and the Council runs as one legal body. Second, whether the translation push, through the EIR programme, the Bio-AI hubs and the BioE3 parks, produces commercial products and not only papers. Third, whether the bioeconomy keeps growing. The latest report puts growth at nearly 18% a year. Going from US$ 195 billion in 2025 to US$ 300 billion in 2030 needs only about 9% a year (our own arithmetic, not a PIB figure), so the target is within reach of the recent trend, as long as the growth is sustained.
🔑 Revision block
The news. Fourth AGM of the BRIC Society, Kartavya Bhawan, New Delhi, 21 November 2026; chair Dr Jitendra Singh (President, BRIC Society); presentation by Dr Rajesh S. Gokhale (Secretary, DBT, and DG, BRIC).
What BRIC is. Autonomous body under DBT (Ministry of Science and Technology), created by merging 14 autonomous institutes on 10 November 2023; Secretariat inaugurated 29 December 2025; handbook of MoA, rules and bye-laws launched at the Fourth AGM; merger of institute societies proposed.
Ranking. First among government institutions in health sciences, second in biological sciences (Nature Index India, second year running). The Nature Index measures output in selected top journals.
Bioeconomy. About US$ 10 billion (2014) to US$ 165.7 billion (2024) to US$ 195.3 billion (2025; 4.8% of GDP); targets US$ 300 billion by 2030 and US$ 1 trillion by 2047; biotech startups over 11,000.
Policy. BioE3 (Biotechnology for Economy, Environment and Employment), Cabinet approval 24 August 2024; biomanufacturing hubs, Bio-AI hubs, biofoundries.
Bodies. DBT (1986) = policy and funding; BRIC (2023) = research institutes; BIRAC (Section 8 company) = startups and industry.
Programmes. BRIC–BIRAC Entrepreneur-in-Residence (launched 10 November 2025); D.E.S.I.G.N. for BioE3 Challenge (over 6,000 proposals); Vaibhav Connect for the scientific diaspora.
🎯 Practice MCQs
Q1. The abbreviation BRIC, in the context of Indian science, stands for:
(a) Biotechnology Research and Industry Council
(b) Biotechnology Research and Innovation Council
(c) Bioscience Research and Innovation Centre
(d) Biological Resources and Innovation Council
→ (b)
BRIC is the Biotechnology Research and Innovation Council. It should not be confused with BRICS, the grouping of nations.
Q2. The Biotechnology Research and Innovation Council was created by bringing together how many autonomous institutions of the Department of Biotechnology?
(a) 8
(b) 10
(c) 12
(d) 14
→ (d)
PIB records 14 autonomous institutions, subsumed on 10 November 2023 with Cabinet approval.
Q3. BRIC functions under which of the following?
(a) Department of Biotechnology
(b) Indian Council of Medical Research
(c) Council of Scientific and Industrial Research
(d) Department of Science and Technology
→ (a)
BRIC is an autonomous body of the Department of Biotechnology, which is part of the Ministry of Science and Technology.
Q4. Consider the following statements about the BioE3 Policy:
1. It was approved by the Union Cabinet in August 2024.
2. BioE3 stands for Biotechnology for Economy, Environment and Employment.
Which of the statements given above is/are correct?
(a) 1 only
(b) 2 only
(c) Both 1 and 2
(d) Neither 1 nor 2
→ (c)
The Cabinet approved the policy on 24 August 2024, and BioE3 expands as Biotechnology for Economy, Environment and Employment. Both statements are correct.
Q5. India's stated target for the size of its bioeconomy by 2047 is:
(a) US$ 100 billion
(b) US$ 300 billion
(c) US$ 500 billion
(d) US$ 1 trillion
→ (d)
The target for 2030 is US$ 300 billion. The 2047 target, in line with Viksit Bharat, is US$ 1 trillion.
Q6. The Entrepreneur-in-Residence programme was launched jointly by BRIC and:
(a) Indian Council of Medical Research
(b) Biotechnology Industry Research Assistance Council
(c) NITI Aayog
(d) Small Industries Development Bank of India
→ (b)
BIRAC, a Section 8 public sector enterprise under DBT, partnered with BRIC on the EIR programme in November 2025.
Q7. The Department of Biotechnology was established in the year:
(a) 1976
(b) 1981
(c) 1986
(d) 1991
→ (c)
DBT marked its 40th Foundation Day on 24 February 2026, which places its founding in 1986.
Q8. The gene therapy trial for haemophilia, supported by the Department of Biotechnology and reported in the New England Journal of Medicine, was conducted at:
(a) Christian Medical College, Vellore
(b) All India Institute of Medical Sciences, New Delhi
(c) Postgraduate Institute of Medical Education and Research, Chandigarh
(d) National Institute of Mental Health and Neurosciences, Bengaluru
→ (a)
The trial at CMC Vellore was announced by Dr Jitendra Singh in December 2024. Haemophilia is an inherited bleeding disorder caused by a missing or faulty clotting factor.
📋 How this gets asked (PYQ pattern)
Science and technology questions in the CDS general knowledge paper come in three recurring forms, and a story like this one feeds each of them.
The first is institutions and acronyms: which body does research, which funds startups, and which ministry each belongs to. DBT, BRIC and BIRAC, or CSIR, ICMR and DST, are the usual cluster, and options are built from near-identical expansions as in Q1.
The second is applied biology: what gene therapy, a vaccine or a biofoundry does, and how a disease such as haemophilia is inherited. These are short conceptual questions, answerable from school-level biology.
The third is numbers and policy names from the latest cycle: the year a policy was approved, its full form, or a target. This cycle's anchors are BioE3 (24 August 2024), US$ 300 billion by 2030 and US$ 1 trillion by 2047.
Preparing for CDS? Make a one-page table of the bodies under the Ministry of Science and Technology and the Ministry of Health, with the year and function of each, and revise the biology behind them in our science study notes. Follow the daily CDS current affairs, and learn with experienced faculty in the upcoming Cavalier courses in Delhi.
Source: PIB / Ministry of Science & Technology, "BRIC aims at USD 300 billion Indian bioeconomy by 2030 and USD 1 trillion by 2047: Dr. Jitendra Singh", 21 November 2026. Background from PIB releases of 24 August 2024 (BioE3 policy), 9 November 2024 (BRIC first Foundation Day), 12 December 2024 (second AGM), 10 and 26 November 2025, 29 December 2025 (BRIC Secretariat), 24 February 2026 (DBT 40th Foundation Day) and 19 March 2026 (India Bioeconomy Report 2026).
✍️ Written by Col D.N. Sharma — Science & general-studies faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk.
